Cholangiocarcinoma PDHA1 succinylation suppresses macrophage antigen presentation via alpha-ketoglutaric acid accumulation
Lists
Only you see this
Abstract
Gemcitabine combined with cisplatin is the first-line chemotherapy for advanced cholangiocarcinoma, but drug resistance remains a challenge, leading to unsatisfactory therapeutic effect. Here, we elucidate the possibility of chemotherapy regimens sensitized by inhibiting succinylation in patients with cholangiocarcinoma from the perspective of post-translational modification. Our omics analysis reveals that succinylation of PDHA1 lysine 83, a key enzyme in the tricarboxylic acid cycle, alters PDH enzyme activity, modulates metabolic flux, and leads to alpha-ketoglutaric acid accumulation in the tumor microenvironment. This process activates the OXGR1 receptor on macrophages, triggering MAPK signaling and inhibiting MHC-II antigen presentation, which promotes immune escape and tumor progression. Moreover, we show that inhibiting PDHA1 succinylation with CPI-613 enhances the efficacy of gemcitabine and cisplatin. Targeting PDHA1 succinylation may be a promising strategy to improve treatment outcomes in cholangiocarcinoma and warrants further clinical exploration.
BibTeX
@inproceedings{zhang2025cholangiocarcinoma,
author = {Ning Zhang and Linmao Sun and Shuo Zhou and Changyong Ji and Tianming Cui and Qi Chu and Jingyang Ye and Shuhang Liang and Kun Ma and Yufeng Liu and Xianying Li and Xinyu Guo and Wei Zhang and Xuetian Gu and Cheng Cheng and Qingrui Zha and Shengwei Tao and Yunguang Zhang and Junhui Chu and Chenghui Wu and Yuchen Zhang and Jiabei Wang and Yao Liu and Lianxin Liu},
title = {{Cholangiocarcinoma PDHA1 succinylation suppresses macrophage antigen presentation via alpha-ketoglutaric acid accumulation}},
booktitle = {Nature Communications},
year = {2025},
doi = {10.1038/s41467-025-58429-7},
}Loading related content...